Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures: FTSE (0.47%), DAX (0.52%), CAC40 (0.62%)

Sep 09 ,2026

  • Synopsis

    • European indices are set to open lower with Asian equities mixed today. South Korea outperforming with Taiwan semis also higher. Japan and Greater China markets little changed. S&P 500 futures flat afterhours. Bonds mixed Treasury yields up slightly at the front end while JGB yields down 1-2 bp.

    • US equities were lower in Tuesday trading as major averages ended near session lows.

    • Middle East tensions pushing crude hitting three-month high. US struck more Iranian oil tankers near Kharg Island in response to latest IRGC missile attack on US naval warship. Earlier rise in oil came after Houthis launched multi-pronged attack on Saudi cities that also dealt damage to oil facilities. Tit-for-tat cycle raising concerns about a wider escalation while Iran pressing ahead with efforts to extend its claims over Strait of Hormuz.

    • Wednesday sees, in central banks, Poland central bank interest rate decision at 15:00CET. Benchmark interest rate is expected to be left unchanged at 3.75%. Hungary central bank publishes the minutes of the last MPC meeting. Riksbank's Seim lecture at 18:00CET at the Economic Museum title 'What is money?'. ECB's Lagarde, Bundesbank's Nagel speeches at 19:00CET at official dinner of Bundesbank.

    • Earnings reported: (ITX.SM) Inditex reports H1 net income attributable €2.98B vs StreetAccount €3.04B. (BIOV.SW) BioVersys reports H1 net income (CHF15.6M) vs FactSet (CHF11.7M)

    • Others today: Benelux: D'Ieteren Group (DIE.BB)

    • DACHs: Medacta Group (MOVE.SW), BioVersys (BIOV.SW), SHL Telemedicine (SHLTN.SW), M1 Kliniken (M12.GR)

    • France: Antin Infrastructure Partners (ANTIN.FP), Seche Environnement (SCHP.FP), Jacquet Metals (JCQ.FP), Lanson-BCC (ALLAN.FP), Haulotte Group (PIG.FP)

    • Nordics: Rusta (RUSTA.SS)

    • Southern Europe: Inditex (ITX.SM), Esprinet (PRT.IM)

    • UK: Spire Healthcare Group (SPI.LN), W.A.G. Payment Solutions (EWG.LN), MHP (MHPC.LN), Gym Group (GYM.LN), ASA International Group (ASAI.LN), Frontier Developments (FDEV.LN), Nexteq (NXQ.LN)

    • Economic: France Jul industrial production, Norway Aug PPI, Greece Aug CPI

  • Politics/Macro/World News

    • Portugal Government Survives Far-Right Chega No-Confidence Vote (BBG )

    • Iran attacks US base in Jordan, ships near Hormuz after tankers sunk (Reuters )

  • Top company news

    • Earnings/updates

      • ITP.FP (Interparfums) -- reports H1 Net Income €65.5M vs FactSet €58.5M

      • ANTIN.FP (Antin Infrastructure Partners) -- reports H1 EPS €0.26 vs year-ago €0.31

      • CRE.LN (Conduit Holdings) -- CEO Neil Eckert to step down; effective 1-Mar-27

      • RUSTA.SS (Rusta) -- reports Q1 EPS SEK1.40 vs FactSet SEK1.30 [4 est, SEK1.10-1.44]

      • PIG.FP (Haulotte Group) -- reports H1 revenue €276M, +5% vs year-ago €264M

      • HOFI.SS (Hoist Finance) -- Hoist Finance's board decides to raise profitability target and adjust dividend policy

      • SAR.GA (GR Sarantis) -- reports H1 adjusted net income €27.7M vs year-ago €29.2M (post EU close 8-Sep)

    • M&A

      • LBIRD.FP (Lumibird) -- signs share purchase agreement for sale of Medical to IPG Photonics Corporation

      • HOLN.SW (Holcim) -- invests in UK-based technology Cloud Cycle; financial details not provided

      • CVC Capital Partners working with Moelis and William Blair on potential sale of Arthea, valuing company ~$2B -- Reuters

    • Healthcare

      • AZN.LN (AstraZeneca) -- Transcript Intelligence: AstraZeneca at European Respiratory Society Congress

      • AZN.LN (AstraZeneca) -- NICE recommends AstraZeneca's Imfinzi with platinum-based chemotherapy for dMMR endometrial cancer, does not recommend it for pMMR endometrial cancer

      • UCB.BB (UCB) -- UCB's CIMZIA receives FDA Breakthrough Therapy designation for antiphospholipid syndrome (APS) in pregnant women

      • AMLX (Amylyx Pharmaceuticals) -- enters into a manufacturing and supply agreement with Bachem Americas, Inc. - 8-K

      • SDZ.SW (Sandoz Group) -- Transcript Intelligence: Sandoz Group Capital Markets Day

      • 4519.JP (Chugai Pharmaceutical) -- NICE does not recommend Chugai's Nemluvio to treat moderate to severe prurigo nodularis

    • Other

      • SAP.GR (SAP) -- Transcript Intelligence: SAP at Goldman Sachs Communacopia + Technology Conference

      • HEIA.NA (Heineken) -- Transcript Intelligence: Heineken at Barclays Global Consumer Staples Conference

      • AENA.SM (Aena S.M.E.) -- Aena notes Spanish Government withdraws its initially proposed veto on the processing of the bill on the co-management of airports of general interest in the Balearic Islands (post EU close 8-Sep)

      • AVOL.SW (Avolta) -- extends long-term travel retail contracts across four Mexican airports

      • CVC.NA (CVC Capital Partners) -- Rob Lucas to step back as CVC Capital Partners CEO by Q1/28

      • DOCM.SW (DocMorris) -- Finance B.V. is launching a private placement of ~ CHF 100M senior unsecured bonds due 2031 to finance early repurchase of Convertible Bonds 2028

      • 57L.GR (Sono Group) -- SEC filing: SCHEDULE 13D (Filed by Kelly Christopher Michael)

  • Key rating changes

    • Upgrades

      • KINV.B.SS (Kinnevik) -- to buy from hold at SEB

      • KRX.ID (Kingspan Group) -- to overweight from neutral at JPMorgan

    • Downgrades

      • NOVN.SW (Novartis) -- to hold from buy at Deutsche Bank

      • COLO.B.DC (Coloplast) -- to underweight from neutral at JPMorgan

      • VEND.NO (Vend Marketplaces) -- to equal-weight from overweight at Morgan Stanley

      • CCC.LN (Computacenter) -- to hold from buy at Investec (14:45 BST)

    • Initiations

      • RICHT.HB (Gedeon Richter) -- neutral at Oddo

    • Other Actions

      • UBI.FP (Ubisoft Entertainment) -- assumed equal-weight at Morgan Stanley; prior rating was equal-weight

  • Data

    • Nikkei (0.35%) to 65042.43

    • Hang Seng (0.42%) to 25211.23

    • Shanghai Composite (0.11%) to 3936.12

    • S&P futures +5.5 vs prior close of 7680.5

    • €-$ +0.0009 or +0.08% to 1.1633

    • $-¥ (0.61) or (0.40%) to 153.38

    • €-¥ (0.57) or (0.32%) to 178.42

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.